-
Something wrong with this record ?
Oncolysate-loaded Escherichia coli bacterial ghosts enhance the stimulatory capacity of human dendritic cells
J. Michalek, R. Hezova, P. Turanek-Knötigova, J. Gabkova, M. Strioga, W. Lubitz, P. Kudela,
Language English Country Germany
Document type Journal Article
NLK
PubMed Central
from 1982
ProQuest Central
from 1997-03-01 to 1 year ago
Medline Complete (EBSCOhost)
from 2000-04-01 to 1 year ago
Health & Medicine (ProQuest)
from 1997-03-01 to 1 year ago
Public Health Database (ProQuest)
from 1997-03-01 to 1 year ago
- MeSH
- Cell Differentiation immunology MeSH
- CD4-Positive T-Lymphocytes immunology MeSH
- CD8-Positive T-Lymphocytes immunology MeSH
- Dendritic Cells immunology microbiology transplantation MeSH
- Escherichia coli immunology MeSH
- Phenotype MeSH
- Glioblastoma immunology therapy MeSH
- Immunotherapy, Adoptive methods MeSH
- Interleukin-12 biosynthesis immunology MeSH
- Humans MeSH
- Lipopolysaccharides pharmacology MeSH
- Cell Line, Tumor MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
The natural adjuvant properties of bacterial ghosts (BGs) lie within the presence of intact pathogen-associated molecular patterns on their surface. BGs can improve the direct delivery, natural processing and presentation of target antigens within dendritic cells (DCs). Moreover, sensitization of human DCs by cancer cell lysate (oncolysate)-loaded BGs in the presence of IFN-α and GM-CSF enhanced DC maturation as indicated by an increased expression of maturation markers and co-stimulatory molecules, higher production of IL-12p70 and stimulation of significantly increased proliferation of both autologous CD4(+) and CD8(+) T cells compared to DCs matured in the presence of purified lipopolysaccharide. The induced T cells efficiently recognized oncolysate-derived tumor-associated antigens expressed by cancer cells used for the production of oncolysate. Our optimized one-step simultaneous antigen delivery and DC maturation-inducing method emerges as a promising tool for the development and implementation of next-generation cellular cancer immunotherapies.
BIRD C GmbH Dr Bohrgasse 2 8 1030 Vienna Austria
Department of Immunology National Cancer Institute Vilnius Lithuania
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc17031280
- 003
- CZ-PrNML
- 005
- 20200812081201.0
- 007
- ta
- 008
- 171025s2017 gw f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s00262-016-1932-4 $2 doi
- 035 __
- $a (PubMed)27864613
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Michalek, Jaroslav $u Cellthera, s.r.o., Brno, Czech Republic. Advanced Cell Immunotherapy Unit, Department of Pharmacology, Medical Faculty, Masaryk University, Brno, Czech Republic. Department of Pediatrics, The University Hospital Brno, Brno, Czech Republic.
- 245 10
- $a Oncolysate-loaded Escherichia coli bacterial ghosts enhance the stimulatory capacity of human dendritic cells / $c J. Michalek, R. Hezova, P. Turanek-Knötigova, J. Gabkova, M. Strioga, W. Lubitz, P. Kudela,
- 520 9_
- $a The natural adjuvant properties of bacterial ghosts (BGs) lie within the presence of intact pathogen-associated molecular patterns on their surface. BGs can improve the direct delivery, natural processing and presentation of target antigens within dendritic cells (DCs). Moreover, sensitization of human DCs by cancer cell lysate (oncolysate)-loaded BGs in the presence of IFN-α and GM-CSF enhanced DC maturation as indicated by an increased expression of maturation markers and co-stimulatory molecules, higher production of IL-12p70 and stimulation of significantly increased proliferation of both autologous CD4(+) and CD8(+) T cells compared to DCs matured in the presence of purified lipopolysaccharide. The induced T cells efficiently recognized oncolysate-derived tumor-associated antigens expressed by cancer cells used for the production of oncolysate. Our optimized one-step simultaneous antigen delivery and DC maturation-inducing method emerges as a promising tool for the development and implementation of next-generation cellular cancer immunotherapies.
- 650 _2
- $a CD4-pozitivní T-lymfocyty $x imunologie $7 D015496
- 650 _2
- $a CD8-pozitivní T-lymfocyty $x imunologie $7 D018414
- 650 _2
- $a buněčná diferenciace $x imunologie $7 D002454
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 _2
- $a dendritické buňky $x imunologie $x mikrobiologie $x transplantace $7 D003713
- 650 _2
- $a Escherichia coli $x imunologie $7 D004926
- 650 _2
- $a glioblastom $x imunologie $x terapie $7 D005909
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a imunoterapie adoptivní $x metody $7 D016219
- 650 _2
- $a interleukin-12 $x biosyntéza $x imunologie $7 D018664
- 650 _2
- $a lipopolysacharidy $x farmakologie $7 D008070
- 650 _2
- $a fenotyp $7 D010641
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Hezova, Renata $u Advanced Cell Immunotherapy Unit, Department of Pharmacology, Medical Faculty, Masaryk University, Brno, Czech Republic.
- 700 1_
- $a Turánek-Knötigová, Pavlína $u Advanced Cell Immunotherapy Unit, Department of Pharmacology, Medical Faculty, Masaryk University, Brno, Czech Republic. Department of Pharmacology and Immunotherapy, Veterinary Research Institute, Brno, Czech Republic. $7 xx0137875
- 700 1_
- $a Gabkova, Jana $u Institute of Mathematics and Physics, Faculty of Mechanical Engineering, Slovak University of Technology, Bratislava, Slovak Republic.
- 700 1_
- $a Strioga, Marius $u Department of Immunology, National Cancer Institute, Vilnius, Lithuania.
- 700 1_
- $a Lubitz, Werner $u BIRD-C GmbH, Dr. Bohrgasse 2-8, 1030, Vienna, Austria.
- 700 1_
- $a Kudela, Pavol $u BIRD-C GmbH, Dr. Bohrgasse 2-8, 1030, Vienna, Austria. pavol.kudela@bird-c.at.
- 773 0_
- $w MED00001041 $t Cancer immunology, immunotherapy CII $x 1432-0851 $g Roč. 66, č. 2 (2017), s. 149-159
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/27864613 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20171025 $b ABA008
- 991 __
- $a 20200812081157 $b ABA008
- 999 __
- $a ok $b bmc $g 1254873 $s 992307
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2017 $b 66 $c 2 $d 149-159 $e 20161118 $i 1432-0851 $m Cancer immunology and immunotherapy $n Cancer Immunol Immunother $x MED00001041
- LZP __
- $a Pubmed-20171025
